Despite strong revenue, the company's high P/S ratio and wea...
Despite strong revenue, the company's high P/S ratio and weaker forecasted growth may concern investors. High share prices may not be sustainable with expected revenue growth. Business prospects may not significantly improve, posing a risk to share price.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment